Foundation Medicine, Inc.

Ross Segan Named OPEQ Director Ross Segan is the new head of the Office of Product Evaluation and Quality (OPEQ) in the US Food and Drug Administration’s Center for Devices and Radiological Health, th

A second approval for Bristol Myers Squibb Company ’s cancer drug Augtyro (repotrectinib) has provided further validation of BMS’s $4.1bn acquisition of Turning Point Therapeutics Inc. in 2022. [Si

Jeraygo (aprocitentan), Idorsia ’s first-of-its-kind treatment for resistant hypertension, is among the latest batch of new drugs that the European Medicines Agency today announced should be approved

The European Medicines Agency is this week deciding whether to recommend pan-EU marketing approval for seven new products, including Idorsia ’s aprocitentan, which last month became the first oral an